Plain-English translation of NCT06850103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment combination for rectal cancer that has spread to a limited number of places in the body (usually the liver). The study combines short-course radiation therapy, a chemotherapy regimen called CAPEOX, and an immunotherapy medication called . The goal is to shrink the cancer before surgery and improve long-term survival.
Most patients with rectal cancer that has spread don't live as long because the distant spread is harder to control than the local cancer. This trial is designed to see if combining the medication with radiation and chemotherapy before surgery—rather than just using chemotherapy alone—can help more patients survive longer.
You likely qualify if…
You likely don't qualify if…
You would first receive short-course radiation therapy to your rectal area, followed by 4 cycles of chemotherapy combined with the immunotherapy medication. After that, you would have surgery to remove your primary tumor and treat the spread areas. Then you would receive 4 more cycles of the same chemotherapy and immunotherapy combination. The entire treatment may take several months, with regular visits for scans, blood tests, and clinical assessments to monitor how you're responding.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China